CoChat

The DOI matches its Crossref record; 79 of the 83 references it cites were found in a registry or an index; 82 of the 155 sources its claims cite were checked for support.

The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors

Open access

Abstract

Testicular germ cell tumors (TGCTs) are cancers with very good prognosis, even in the metastatic setting, with high curative potential mainly attributed to the introduction of cisplatin-based chemotherapy. However, approximately 15% of the patients develop platinum-refractory disease and suffer multiple relapses. Therefore, there is an unmet need for novel therapeutic agents with improved efficacy and minimal long-term side effects. Recent advances in the development of immunotherapeutic agents, particularly immune checkpoint inhibitors (ICIs), have offered an opportunity to test their activity in various tumor types, including GCTs. This review aims to analyze the immune microenvironment of these tumors and present the most recently available data from studies that have tested immunotherapeutic agents against GCTs. The majority of the available knowledge derives from case reports or small cohort studies, particularly those involving ICIs of the PD-1/PD-L1 axis alone or in combination with anti-CTLA-4 monoclonal antibodies. Other immunotherapeutic targeted approaches, including antibody-drug conjugates, antibody prodrugs, vaccines, tyrosine kinase inhibitors, chimeric antigen receptor (CAR) T-cell therapy, have biological rationales and have shown preliminary activity or are currently being tested. Growing evidence on these and other approaches will assist in broadening the currently limited treatment armamentarium against platinum-refractory TGCTs.

Overview

CoChat Summary

## TL;DR

This is a systematic review of the immune microenvironment of testicular germ cell tumors (TGCTs) and the very limited clinical evidence for immunotherapy in platinum-refractory disease. The paper concludes that current immune checkpoint inhibitor results are mostly disappointing, but biomarker-driven trials and newer approaches such as antibody-drug conjugates, prodrugs, vaccines, and CAR-T cells may expand treatment options.

## Key findings

  • Approximately 15% of patients with TGCTs develop platinum-refractory disease; the authors also state that one-fifth of patients with advanced TGCTs develop platinum-refractory disease.
  • In a case series of 7 platinum-refractory patients treated with nivolumab or pembrolizumab, 4 died after a single dose, while 2 had long-term tumor response associated with high PD-L1 expression.
  • In a phase II study of 12 cisplatin-refractory patients treated with pembrolizumab, there were no partial or complete responses; 2/12 had stable disease lasting 28 and 19 weeks.
  • In a phase II study of 8 patients treated with avelumab, all progressed within 2.6 months; median PFS was 0.9 months and median OS was 2.7 months. A durvalumab ± tremelimumab trial enrolled 22 patients; the combination arm had 1 partial response and 1 stable disease with serologic improvement.
  • For brentuximab vedotin, one study of 7 CD30-overexpressing patients reported 2 objective responses (1 complete, 1 partial), but a later 18-patient phase II study found no partial or complete responses; median PFS was 1.2 months in CD30-positive patients and 1.4 months in CD30-negative patients.

## Methods

  • Design: Systematic review conducted according to PRISMA guidelines; the study was not registered.
  • Data/sample: Literature search in PubMed and Web of Science using terms related to TGCTs, immunotherapy, PD-L1, CTLA-4, platinum-resistant, and platinum-refractory disease.
  • Main analysis: Narrative synthesis of the immune landscape of TGCTs and the preclinical/clinical evidence for immunotherapeutic strategies, with emphasis on published case reports, small cohorts, and early-phase trials.

## Limitations

  • The paper explicitly states that randomized data are largely absent in advanced TGCTs, and that the best available evidence comes from small cohort studies and case reports.
  • The authors note that the review was not registered.
  • Evidence for many emerging approaches is described as preliminary or based on biological rationale rather than definitive clinical proof (evident from the text).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers16020428

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (A) Oncoplot of immune-mediator gene alterations in TGCTs from the TCGA database. (B) Distribution of immune-mediator gene alterations in seminomatous and non-seminomatous GCTs.
Figure 1 (A) Oncoplot of immune-mediator gene alterations in TGCTs from the TCGA database. (B) Distribution of immune-mediator gene alterations in seminomatous and non-seminomatous GCTs.CC BY · PubMed Central

Verification

Claims the paper makes

74 Valid · 4 Not valid · 55 Not checked · 13 Own results and interpretations

102 more claims · 54 with their cited sources checked

Create a free account to see all 146 claims and to verify the 20 references still open.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 26
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 83 references

Cited by

See all 11

Metadata

Authors
Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J.
Affiliations
  • University of Thessaly (GR)
  • Aberdeen Royal Infirmary (GB)
Corresponding author
Vlachostergios, Panagiotis J.
Venue
Cancers
Publisher
MDPI AG
Published
2024-01-19
Volume
16
Issue
2
Pages
428
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4391029848
Cited by
11
References
83
Citations by year
2026: 7 · 2025: 3 · 2024: 1
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Testicular diseases and treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
testicular germ cell tumors, platinum-refractory disease, immune microenvironment, immune checkpoint inhibitors, PD-1/PD-L1 axis, anti-CTLA-4 monoclonal antibody, antibody-drug conjugates, cancer vaccines, tyrosine kinase inhibitors, CAR T-cell therapy, immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors. https://app.cochat.ai/papers/10.3390/cancers16020428
The paper
Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J. (2024). The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors. Cancers. https://doi.org/10.3390/cancers16020428

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.